Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL177909 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366664-A1 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | GC Cell Corporation (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20240197778-A1 | TREATMENT OF CANCER WITH NK CELLS AND A HER2 TARGETED ANTIBODY | GC Cell Corporation (KR) | 2024-06-20 | — | — | US | disclosed |
| US-20240000840-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | GC Cell Corporation (KR) | 2024-01-04 | — | — | US | disclosed |
| US-20230065416-A1 | CLATHRIN-CHIMETIC ANTIBODY RECEPTOR CONSTRUCTS FOR IMMUNE CELL ACTIVATION THERAPY IN VIVO | NANOTOMER, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022216144-A1 | FUSION PROTEINS COMPRISING CHIMERIC ANTIGEN RECEPTORS AND IL-15 | GC Cell Corporation (KR) | 2022-10-13 | — | — | WO | disclosed |
| US-20220265556-A1 | LIPOSOMAL DOXORUBICIN FORMULATION, METHOD FOR PRODUCING A LIPOSOMAL DOXORUBICIN FORMULATION AND USE OF A LIPOSOMAL DOXORUBICIN FORMULATION AS A MEDICAMENT | INNOMEDICA HOLDING AG (CH) | 2022-08-25 | — | — | US | disclosed |
| EP-3753549-A1 | LIPOSOMAL DOXORUBICIN FORMULATION, METHOD FOR PRODUCING A LIPOSOMAL DOXORUBICIN FORMULATION AND USE OF A LIPOSOMAL DOXORUBICIN FORMULATION AS A MEDICAMENT | InnoMedica Holding AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-0693485-B1 | Baccatin derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1998-06-03 | — | — | EP | disclosed |
| EP-0693485-A2 | Baccatin derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265556-A1 | LIPOSOMAL DOXORUBICIN FORMULATION, METHOD FOR PRODUCING A LIPOSOMAL DOXORUBICIN FORMULATION AND USE OF A LIPOSOMAL DOXORUBICIN FORMULATION AS A MEDICAMENT | LPXN, DLST, XIAP | TUBB4A 498/4885TUBB 203/4885TUBA3C 677/4885 |
| US-20230065416-A1 | CLATHRIN-CHIMETIC ANTIBODY RECEPTOR CONSTRUCTS FOR IMMUNE CELL ACTIVATION THERAPY IN VIVO | CLTC, CLTA, CLTB | TUBB4A 3776/4885TUBB 3825/4885TUBA3C 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.